Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-14205
Grimmelt, A C; Cohen, C D; Fehr, T; Serra, A L; Wüthrich, R P (2009). Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clinical Nephrology, 71(2):125-129.
|PDF - Registered users only|
BACKGROUND: Iron deficiency is common in patients with chronic kidney disease and in kidney transplant recipients. PATIENTS AND METHODS: We analyzed the safety and tolerability of the new intravenous iron preparation ferric carboxymaltose (FCM) in these two patient groups. Adverse events after administration of the drug were assessed by using a questionnaire. Vital signs and laboratory data were collected before and after the application of FCM. A total of 46 FCM doses were applied to 44 patients (17 with chronic kidney disease and 27 kidney transplant recipients) either as single injection of 100 or 200 mg (n = 42) or as short infusion with up to 500 mg (n = 4). RESULTS: Mild and transient adverse events (metallic taste, headache, dizziness) occurred in six patients. The estimated glomerular filtration rate remained unchanged by the FCM administration. CONCLUSION: We conclude that safety and tolerability of FCM were excellent. Compared with other intravenous iron preparations the considerably shorter administration time of FCM allows to save time and to reduce costs.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Nephrology|
|DDC:||610 Medicine & health|
|Deposited On:||06 Apr 2009 18:15|
|Last Modified:||27 Nov 2013 18:06|
|Publisher:||Dustri-Verlag Dr Karl Feistle|
|Citations:||Web of Science®. Times cited: 9|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page